{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:39:44Z","timestamp":1793029184280,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xiaoke Li","award":["82174341"],"award-info":[{"award-number":["82174341"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The etiology of nonalcoholic fatty liver disease (NAFLD) involves a complex interaction of genetic and environmental factors. Previous observational studies have revealed that higher leptin levels are related to a lower risk of developing NAFLD, but the causative association remains unknown. We intended to study the causal effect between leptin and NAFLD using the Mendelian randomization (MR) study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a two-sample Mendelian randomization (TSMR) analysis using summary GWAS data from leptin (up to 50,321 individuals) and NAFLD (8,434 cases and 770,180 controls) in a European population. Instrumental variables (IVs) that satisfied the three core assumptions of Mendelian randomization were selected. The TSMR analysis was conducted using the inverse variance weighted (IVW) method, MR-Egger regression method, and weighted median (WM) method. To ensure the accuracy and stability of the study results, heterogeneity tests, multiple validity tests, and sensitivity analyses were conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The findings of the TSMR correlation analysis between NAFLD and leptin were as follows: IVW method (odds ratio (OR) 0.6729; 95% confidence interval (95% CI) 0.4907\u20130.9235; <jats:italic>P<\/jats:italic>\u2009=\u20090.0142), WM method (OR 0.6549; 95% CI 0.4373\u20130.9806; <jats:italic>P<\/jats:italic>\u2009=\u20090.0399), and MR-Egger regression method (<jats:italic>P<\/jats:italic>\u2009=\u20090.6920). Additionally, the findings of the TSMR correlation analysis between NAFLD and circulating leptin levels adjusted for body mass index (BMI) were as follows: IVW method (OR 0.5876; 95% CI 0.3781\u20130.9134; <jats:italic>P<\/jats:italic>\u2009=\u20090.0181), WM method (OR 0.6074; 95% CI 0.4231\u20130.8721; <jats:italic>P<\/jats:italic>\u2009=\u20090.0069), and MR-Egger regression method (<jats:italic>P<\/jats:italic>\u2009=\u20090.8870). It has also been shown that higher levels of leptin are causally linked to a lower risk of developing NAFLD, suggesting that leptin may serve as a protective factor for NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using TSMR analysis and the GWAS database, we investigated the genetic relationship between elevated leptin levels and lowered risk of NAFLD in this study. However, further research is required to understand the underlying mechanisms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01147-x","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T08:01:38Z","timestamp":1688371298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Association between leptin and NAFLD: a two-sample Mendelian randomization study"],"prefix":"10.1186","volume":"28","author":[{"given":"Ziwei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong\u2019an","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"issue":"6","key":"1147_CR1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382.","journal-title":"Hepatology"},{"issue":"1","key":"1147_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"3","key":"1147_CR3","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/ijms24032844","volume":"24","author":"X Yin","year":"2023","unstructured":"Yin X, Guo X, Liu Z, Wang J. Advances in the diagnosis and treatment of non-alcoholic fatty liver disease. Int J Mol Sci. 2023;24(3):2844.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1147_CR4","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1136\/gut.2008.171280","volume":"58","author":"AE Feldstein","year":"2009","unstructured":"Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58(11):1538\u201344.","journal-title":"Gut"},{"issue":"2","key":"1147_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med. 2022;292(2):190\u2013204.","journal-title":"J Intern Med"},{"issue":"2","key":"1147_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68(2):335\u201352.","journal-title":"J Hepatol"},{"issue":"1","key":"1147_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","volume":"15","author":"BA Neuschwander-Tetri","year":"2017","unstructured":"Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45.","journal-title":"BMC Med"},{"issue":"1","key":"1147_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/hep.32534","volume":"77","author":"Z Ren","year":"2023","unstructured":"Ren Z, Simons P, Wesselius A, Stehouwer CDA, Brouwers M. Relationship between NAFLD and coronary artery disease: a Mendelian randomization study. Hepatology. 2023;77(1):230\u20138.","journal-title":"Hepatology"},{"issue":"1","key":"1147_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1147_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","volume":"17","author":"M Eslam","year":"2020","unstructured":"Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17(1):40\u201352.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"1147_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461\u20135.","journal-title":"Nat Genet"},{"issue":"7","key":"1147_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/biomedicines9070762","volume":"9","author":"C Jim\u00e9nez-Cortegana","year":"2021","unstructured":"Jim\u00e9nez-Cortegana C, Garc\u00eda-Galey A, Tami M, Del Pino P, Carmona I, L\u00f3pez S, Alba G, S\u00e1nchez-Margalet V. Role of leptin in non-alcoholic fatty liver disease. Biomedicines. 2021;9(7):762.","journal-title":"Biomedicines"},{"issue":"1","key":"1147_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","volume":"64","author":"SA Polyzos","year":"2015","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metab Clin Exp. 2015;64(1):60\u201378.","journal-title":"Metab Clin Exp"},{"issue":"4","key":"1147_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3350\/cmh.2018.0011","volume":"24","author":"L Rotundo","year":"2018","unstructured":"Rotundo L, Persaud A, Feurdean M, Ahlawat S, Kim HS. The Association of leptin with severity of non-alcoholic fatty liver disease: a population-based study. Clin Mol Hepatol. 2018;24(4):392\u2013401.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"1147_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00125-015-3769-3","volume":"59","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59(1):30\u201343.","journal-title":"Diabetologia"},{"issue":"1","key":"1147_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3803\/EnM.2018.33.1.33","volume":"33","author":"C Boutari","year":"2018","unstructured":"Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab. 2018;33(1):33\u201343.","journal-title":"Endocrinol Metab"},{"issue":"8","key":"1147_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms18081649","volume":"18","author":"TE Adolph","year":"2017","unstructured":"Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18(8):1649.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1147_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1053\/jhep.2001.26518","volume":"34","author":"K Ikejima","year":"2001","unstructured":"Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34(2):288\u201397.","journal-title":"Hepatology"},{"issue":"5","key":"1147_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.dld.2020.10.025","volume":"53","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Wang J, Huang F, Yao Y, Xu L. Leptin induces NAFLD progression through infiltrated CD8+ T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages. Digest Liver Dis. 2021;53(5):598\u2013605.","journal-title":"Digest Liver Dis"},{"issue":"1","key":"1147_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith GD, Ebrahim S. \u201cMendelian randomization\u201d: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1\u201322.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1147_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ije\/dyh132","volume":"33","author":"GD Smith","year":"2004","unstructured":"Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30\u201342.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"1147_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"10","author":"J Bowden","year":"2019","unstructured":"Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods. 2019;10(4):486\u201396.","journal-title":"Res Synth Methods"},{"key":"1147_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.681396","volume":"11","author":"JZ Guo","year":"2021","unstructured":"Guo JZ, Xiao Q, Gao S, Li XQ, Wu QJ, Gong TT. Review of mendelian randomization studies on ovarian cancer. Front Oncol. 2021;11: 681396.","journal-title":"Front Oncol"},{"issue":"2","key":"1147_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10654-020-00622-7","volume":"35","author":"G Davey Smith","year":"2020","unstructured":"Davey Smith G, Holmes MV, Davies NM, Ebrahim S. Mendel\u2019s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues. Eur J Epidemiol. 2020;35(2):99\u2013111.","journal-title":"Eur J Epidemiol"},{"issue":"19","key":"1147_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318(19):1925\u20136.","journal-title":"JAMA"},{"issue":"1","key":"1147_CR26","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a040501","volume":"12","author":"RC Richmond","year":"2022","unstructured":"Richmond RC, Davey Smith G. Mendelian randomization: concepts and scope. Cold Spring Harb Perspect Med. 2022;12(1): a040501.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"1147_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","volume":"30","author":"S Burgess","year":"2015","unstructured":"Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543\u201352.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"1147_CR28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ije\/dyx028","volume":"45","author":"FP Hartwig","year":"2016","unstructured":"Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45(6):1717\u201326.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"1147_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ije\/dyq151","volume":"40","author":"BL Pierce","year":"2011","unstructured":"Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740\u201352.","journal-title":"Int J Epidemiol"},{"key":"1147_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7: e34408.","journal-title":"Elife"},{"issue":"12","key":"1147_CR31","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.2337\/db20-0070","volume":"69","author":"H Yaghootkar","year":"2020","unstructured":"Yaghootkar H, Zhang Y, Spracklen CN, Karaderi T, Huang LO, Bradfield J, Schurmann C, Fine RS, Preuss MH, Kutalik Z, et al. Genetic studies of leptin concentrations implicate leptin in the regulation of early adiposity. Diabetes. 2020;69(12):2806\u201318.","journal-title":"Diabetes"},{"issue":"5","key":"1147_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","volume":"36","author":"AR Carter","year":"2021","unstructured":"Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, Taylor AE, Davies NM, Howe LD. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36(5):465\u201378.","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"1147_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100437","volume":"2","author":"N Ghodsian","year":"2021","unstructured":"Ghodsian N, Abner E, Emdin CA, Gobeil \u00c9, Taba N, Haas ME, Perrot N, Manikpurage HD, Gagnon \u00c9, Bourgault J, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med. 2021;2(11): 100437.","journal-title":"Cell Rep Med"},{"issue":"4","key":"1147_CR34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/ije\/dyx002","volume":"47","author":"H van Kippersluis","year":"2018","unstructured":"van Kippersluis H, Rietveld CA. Pleiotropy-robust Mendelian randomization. Int J Epidemiol. 2018;47(4):1279\u201388.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"1147_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/hep.32183","volume":"75","author":"L Chen","year":"2022","unstructured":"Chen L, Yang H, Li H, He C, Yang L, Lv G. Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study. Hepatology. 2022;75(4):785\u201396.","journal-title":"Hepatology"},{"issue":"R1","key":"1147_CR36","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"1147_CR37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","volume":"37","author":"S Yuan","year":"2022","unstructured":"Yuan S, Chen J, Li X, Fan R, Arsenault B, Gill D, Giovannucci EL, Zheng JS, Larsson SC. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study. Eur J Epidemiol. 2022;37(7):723\u201333.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"1147_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304\u201314.","journal-title":"Genet Epidemiol"},{"issue":"2","key":"1147_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"1147_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"224","key":"1147_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008601","volume":"6","author":"NE Allen","year":"2014","unstructured":"Allen NE, Sudlow C, Peakman T, Collins R. UK biobank data: come and get it. Sci Transl Med. 2014;6(224): 224ed224.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1147_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377\u201389.","journal-title":"Eur J Epidemiol"},{"key":"1147_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.896499","volume":"9","author":"S Huang","year":"2022","unstructured":"Huang S, Huang F, Mei C, Tian F, Fan Y, Bao J. Systemic lupus erythematosus and the risk of cardiovascular diseases: a two-sample Mendelian randomization study. Front Cardiovasc Med. 2022;9: 896499.","journal-title":"Front Cardiovasc Med"},{"key":"1147_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.844733","volume":"9","author":"Q Li","year":"2022","unstructured":"Li Q, Yan S, Li Y, Kang H, Zhu H, Lv C. Mendelian randomization study of heart failure and stroke subtypes. Front Cardiovasc Med. 2022;9: 844733.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"1147_CR45","first-page":"1961","volume":"45","author":"J Bowden","year":"2016","unstructured":"Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961\u201374.","journal-title":"Int J Epidemiol"},{"key":"1147_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Holmes MV, Minelli C, Relton CL, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 2019;4:186.","journal-title":"Wellcome Open Res"},{"issue":"3","key":"1147_CR47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755\u201364.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"1147_CR48","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1991.","journal-title":"Gastroenterology"},{"issue":"1","key":"1147_CR49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"12","key":"1147_CR50","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/biomedicines9121890","volume":"9","author":"A Ismaiel","year":"2021","unstructured":"Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The visceral adiposity index in non-alcoholic fatty liver disease and liver fibrosis-systematic review and meta-analysis. Biomedicines. 2021;9(12):1890.","journal-title":"Biomedicines"},{"issue":"6","key":"1147_CR51","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom12060824","volume":"12","author":"F Nassir","year":"2022","unstructured":"Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules. 2022;12(6):824.","journal-title":"Biomolecules"},{"issue":"8","key":"1147_CR52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de L\u00e9dinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"1147_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease\u2014a global public health perspective. J Hepatol. 2019;70(3):531\u201344.","journal-title":"J Hepatol"},{"issue":"3","key":"1147_CR54","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.clnu.2018.08.008","volume":"38","author":"AY Wang","year":"2019","unstructured":"Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr. 2019;38(3):975\u201381.","journal-title":"Clin Nutr"},{"issue":"5","key":"1147_CR55","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/ijms22052350","volume":"22","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: state of art. Int J Mol Sci. 2021;22(5):2350.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1147_CR56","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jacc.2020.11.069","volume":"77","author":"N Perakakis","year":"2021","unstructured":"Perakakis N, Farr OM, Mantzoros CS. Leptin in leanness and obesity: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(6):745\u201360.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1147_CR57","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.2741\/3885","volume":"16","author":"J Wauman","year":"2011","unstructured":"Wauman J, Tavernier J. Leptin receptor signaling: pathways to leptin resistance. Front Biosci. 2011;16(7):2771\u201393.","journal-title":"Front Biosci"},{"issue":"11","key":"1147_CR58","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.tem.2010.08.002","volume":"21","author":"MG Myers Jr","year":"2010","unstructured":"Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21(11):643\u201351.","journal-title":"Trends Endocrinol Metab"},{"issue":"18","key":"1147_CR59","doi-asserted-by":"publisher","first-page":"11848","DOI":"10.1073\/pnas.182420899","volume":"99","author":"Y Lee","year":"2002","unstructured":"Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, Witters LA, Unger RH. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci USA. 2002;99(18):11848\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"40","key":"1147_CR60","doi-asserted-by":"publisher","first-page":"17391","DOI":"10.1073\/pnas.1008025107","volume":"107","author":"T Fujikawa","year":"2010","unstructured":"Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci USA. 2010;107(40):17391\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1147_CR61","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1210\/en.2009-0445","volume":"150","author":"J German","year":"2009","unstructured":"German J, Kim F, Schwartz GJ, Havel PJ, Rhodes CJ, Schwartz MW, Morton GJ. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology. 2009;150(10):4502\u201311.","journal-title":"Endocrinology"},{"issue":"9","key":"1147_CR62","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/j.1478-3231.2009.02022.x","volume":"29","author":"M Lemoine","year":"2009","unstructured":"Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29(9):1431\u20138.","journal-title":"Liver Int"},{"issue":"110\u2013111","key":"1147_CR63","first-page":"1703","volume":"58","author":"D Xu","year":"2011","unstructured":"Xu D, Huang XD, Yuan JP, Wu J, Fan Y, Luo HS, Yang YH. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD. Hepatogastroenterology. 2011;58(110\u2013111):1703\u20137.","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"1147_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1530\/eje.1.01821","volume":"152","author":"C Pagano","year":"2005","unstructured":"Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152(1):113\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1147_CR65","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/oby.2009.89","volume":"17","author":"SR Kashyap","year":"2009","unstructured":"Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity. 2009;17(9):1696\u2013701.","journal-title":"Obesity"},{"issue":"12","key":"1147_CR66","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1111\/j.1572-0241.2003.08767.x","volume":"98","author":"N Chalasani","year":"2003","unstructured":"Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98(12):2771\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1147_CR67","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/j.1478-3231.2006.01337.x","volume":"26","author":"A Cay\u00f3n","year":"2006","unstructured":"Cay\u00f3n A, Crespo J, Mayorga M, Guerra A, Pons-Romero F. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. Liver Int. 2006;26(9):1065\u201371.","journal-title":"Liver Int"},{"issue":"7499","key":"1147_CR68","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1136\/bmj.330.7499.1076","volume":"330","author":"G Davey Smith","year":"2005","unstructured":"Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ. 2005;330(7499):1076\u20139.","journal-title":"BMJ"},{"key":"1147_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3542","volume":"358","author":"T Tillmann","year":"2017","unstructured":"Tillmann T, Vaucher J, Okbay A, Pikhart H, Peasey A, Kubinova R, Pajak A, Tamosiunas A, Malyutina S, Hartwig FP, et al. Education and coronary heart disease: Mendelian randomisation study. BMJ. 2017;358: j3542.","journal-title":"BMJ"},{"issue":"2","key":"1147_CR70","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41366-020-00678-1","volume":"45","author":"KP Huang","year":"2021","unstructured":"Huang KP, Goodson ML, Vang W, Li H, Page AJ, Raybould HE. Leptin signaling in vagal afferent neurons supports the absorption and storage of nutrients from high-fat diet. Int J Obes. 2021;45(2):348\u201357.","journal-title":"Int J Obes"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01147-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T09:04:57Z","timestamp":1688375097000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01147-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01147-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}